Signal 01
Canada's Next AI Advantage May Be Biology
Canada's artificial intelligence opportunity is beginning to move beyond language models, software and computing infrastructure into biology and drug discovery. Toronto based Biossil has raised US$153 million at a US$1 billion valuation to expand an AI assisted approach that identifies promising drug candidates that were previously abandoned. At the same time, Canadian companies and research institutions including BenchSci and Mila are developing AI capable of biological inference, hypothesis generation and experimental prediction. Together, these developments point toward an emerging market where Canadian AI could help create valuable medicines, scientific discoveries and intellectual property rather than simply improve existing digital processes.
What happened
Biossil's new financing, led by the OpenAI Startup Fund, gives the Toronto company significant capital to expand clinical development and acquire additional drug candidates. Biossil uses AI to examine molecules that did not successfully reach market and identify cases where the underlying science may still have value because the original trial, patient population, endpoint or intended use was wrong. The company has already bought or licensed 12 molecules and is working with research institutions in Canada, the United States and Europe. Meanwhile, Toronto based BenchSci is moving toward increasingly autonomous scientific discovery. Its EMET platform is designed to reason across biological evidence, while its Hypothesis Generation Agent has already proposed previously untested drug combinations that received initial experimental support. BenchSci's collaboration with Mila is also focused on AI for biological inference. The emerging market is therefore broader than one company. AI is beginning to participate directly in how biological discoveries are identified, tested and developed.
Why it matters for Canada
Canada has an unusual combination of assets that could matter in this market: globally recognized AI research, major universities, research hospitals, life sciences expertise, biotechnology companies, clinical research capacity and a growing AI ecosystem. The economic opportunity is different from simply applying AI to make an existing business more efficient. If AI helps identify a successful therapy or biological target, the resulting intellectual property can become an extremely valuable asset. That creates a strategic question for Canada. The country has historically produced important research and talent while struggling to retain the companies, intellectual property and economic value that emerge from them. AI biotech offers an opportunity to connect Canadian strengths in artificial intelligence and life sciences while building more of the resulting commercial value in Canada.
What CCN sees
The signal is not simply that AI is entering healthcare. That transition is already well underway. The more important development is that AI is beginning to participate directly in scientific discovery and the creation of biological assets. Canada has many of the ingredients required to compete, including AI research, life sciences expertise, hospitals, clinical capacity, talent and increasingly significant private capital. If these capabilities can be connected and commercialized domestically, AI biotech could become one of Canada's most strategically valuable AI markets. The challenge is ensuring Canada does not simply provide the research and talent while ownership, intellectual property and economic value migrate elsewhere.
What leaders should consider
Business leaders should look beyond the pharmaceutical sector when considering this market. AI infrastructure providers, cloud companies, cybersecurity firms, hospitals, universities, investors, laboratories, data companies and intellectual property specialists could all become part of the AI biotech ecosystem. Scientific and clinical data will become increasingly valuable, while the systems capable of interpreting that data may themselves become strategic assets. This also creates new cybersecurity and digital trust requirements. Biological research, patient information, clinical data, proprietary models and AI generated discoveries could become increasingly valuable targets. Organizations participating in this market will need to think about ownership, security, provenance, privacy and control alongside scientific performance.
What to watch next
Watch Biossil's clinical results rather than simply its valuation. The real test for AI biotech will be whether AI assisted discovery consistently produces therapies that succeed through clinical development. Several companies have already taken AI designed drug candidates into trials, but the sector has yet to demonstrate that an AI designed drug can successfully reach the market. Also watch BenchSci's movement toward autonomous scientific reasoning and whether its hypothesis generation capabilities translate into validated discoveries. More broadly, watch whether Canadian hospitals, research institutions, AI companies and investors form deeper commercialization partnerships and whether Canadian intellectual property remains in Canada as companies scale.
Source: https://archive.vn/2026.09.28-130708/https%3A/www.theglobeandmail.com/business/article-biossil-drugs-raises-153-million-openai-funding/
Signal 02
AI Is Leaving the Screen and Entering the Physical Economy
Artificial intelligence is beginning to move from generating and interpreting information toward understanding and acting in the physical world. AMD's agreement to acquire Fei Fei Li's World Labs for approximately US$8.2 billion provides a major global marker for this transition. World Labs develops spatial intelligence and world models designed to help AI understand three dimensional environments and physical interactions. Canada already has significant capabilities in this emerging physical AI market through companies including Waabi and Sanctuary AI, alongside broader strengths in robotics, autonomous systems, transportation, manufacturing, aerospace, defence and critical infrastructure.
What happened
AMD has entered into a definitive agreement to acquire World Labs in an all stock transaction valued at approximately US$8.2 billion. The acquisition brings one of the world's leading spatial intelligence research teams into a major semiconductor company and signals growing expectations that the next generation of AI computing will extend beyond language and digital information into systems capable of understanding and interacting with physical environments. Canada already has companies pursuing this transition. Toronto based Waabi raised US$750 million earlier this year and secured an additional milestone based future investment of up to US$250 million from Uber as it expands its physical AI platform from autonomous trucking into robotaxis. Uber and Waabi plan for at least 25,000 Waabi Driver powered robotaxis over time. Vancouver based Sanctuary AI is taking another route by deploying physical AI on industrial robotic systems. It reported a greater than 99.5 percent success rate on a complex automotive production task while operating at the customer's required production cycle time. These developments suggest physical AI is moving from research toward commercial deployment across transportation and industry.
Why it matters for Canada
Physical AI aligns unusually well with Canada's economic and industrial base. Canada has significant industries in transportation, mining, energy, agriculture, aerospace, defence, manufacturing, logistics and critical infrastructure. These are precisely the environments where machines capable of seeing, reasoning, navigating and acting autonomously could create significant economic value. This gives Canada an opportunity to connect its established AI research capabilities with industries and physical assets it already operates at scale. The opportunity could include autonomous trucks, intelligent industrial robots, inspection systems, drones, mining equipment, agricultural machinery, defence systems and autonomous technologies operating around critical infrastructure. Canada therefore has an opportunity not simply to consume physical AI, but to build companies, intellectual property and industrial capabilities around it.
What CCN sees
AI is beginning to cross an important boundary between understanding information and acting on the physical world. Canada should pay particular attention because this transition intersects with areas where the country already possesses meaningful capability, including AI research, robotics, aerospace, transportation, manufacturing, mining, energy and defence. Waabi, Sanctuary AI and Canada's broader autonomous systems ecosystem suggest the country is not starting from zero. The strategic opportunity is to connect these capabilities before physical AI becomes another market dominated elsewhere. The next generation of AI leadership may not be defined only by who builds the most powerful model. It may also be defined by who builds, secures and controls the machines that can safely use intelligence in the real world.
What leaders should consider
Business leaders should recognize that physical AI creates a different risk and opportunity profile from generative AI. When a software model produces an incorrect answer, the consequences may remain digital. When an autonomous vehicle, industrial robot, drone or intelligent machine makes an incorrect decision, the consequences can involve people, equipment, production systems and critical infrastructure. Cybersecurity, identity, authorization, sensor integrity, communications security, software assurance, supply chains and human override mechanisms therefore become fundamental parts of the physical AI market. Companies operating industrial assets should begin considering not only where autonomous systems could improve productivity, but how those systems will be secured, governed, monitored and trusted.
What to watch next
Watch whether the World Labs transaction accelerates investment into spatial intelligence, world models, robotics and autonomous systems. In Canada, Waabi will be an important test of whether a common AI architecture can successfully operate across autonomous trucks, robotaxis and eventually additional physical systems. Sanctuary AI's industrial deployments should also be watched closely because existing factories and industrial robots could provide a faster path to commercial adoption than waiting for general purpose humanoid robots. More broadly, watch Canadian defence, mining, energy, transportation, manufacturing and infrastructure organizations for increasing adoption of autonomous systems. Capital, procurement and cybersecurity requirements around these deployments could help determine whether Canada develops a significant domestic physical AI industry or primarily imports the technology.
Source: https://newsroom.amd.com/news/amd-acquire-world-labs/